CHU de Poitiers, Service d'Accueil des Urgences et SAMU 86.
INSERM, CIC-1402, IS-ALIVE.
Eur J Emerg Med. 2024 Aug 1;31(4):267-275. doi: 10.1097/MEJ.0000000000001128. Epub 2024 Feb 16.
Whether high-flow nasal oxygen can improve clinical signs of acute respiratory failure in acute heart failure (AHF) is uncertain.
To compare the effect of high-flow oxygen with noninvasive ventilation (NIV) on respiratory rate in patients admitted to an emergency department (ED) for AHF-related acute respiratory failure.
DESIGN, SETTINGS AND PARTICIPANTS: Multicenter, randomized pilot study in three French EDs. Adult patients with acute respiratory failure due to suspected AHF were included. Key exclusion criteria were urgent need for intubation, Glasgow Coma Scale <13 points or hemodynamic instability.
Patients were randomly assigned to receive high-flow oxygen (minimum 50 l/min) or noninvasive bilevel positive pressure ventilation.
The primary outcome was change in respiratory rate within the first hour of treatment and was analyzed with a linear mixed model. Secondary outcomes included changes in pulse oximetry, heart rate, blood pressure, blood gas samples, comfort, treatment failure and mortality.
Among the 145 eligible patients in the three participating centers, 60 patients were included in the analysis [median age 86 (interquartile range (IQR), 90; 92) years]. There was a median respiratory rate of 30.5 (IQR, 28; 33) and 29.5 (IQR, 27; 35) breaths/min in the high-flow oxygen and NIV groups respectively, with a median change of -10 (IQR, -12; -8) with high-flow nasal oxygen and -7 (IQR, -11; -5) breaths/min with NIV [estimated difference -2.6 breaths/min (95% confidence interval (CI), -0.5-5.7), P = 0.052] at 60 min. There was a median SpO 2 of 95 (IQR, 92; 97) and 96 (IQR, 93; 97) in the high-flow oxygen and NIV groups respectively, with a median change at 60 min of 2 (IQR, 0; 5) with high-flow nasal oxygen and 2 (IQR, -1; 5) % with NIV [estimated difference 0.8% (95% CI, -1.1-2.8), P = 0.60]. PaO 2 , PaCO 2 and pH did not differ at 1 h between groups, nor did treatment failure, intubation and mortality rates.
In this pilot study, we did not observe a statistically significant difference in changes in respiratory rate among patients with acute respiratory failure due to AHF and managed with high-flow oxygen or NIV. However, the point estimate and its large confidence interval may suggest a benefit of high-flow oxygen.
NCT04971213 ( https://clinicaltrials.gov ).
高流量鼻氧疗是否能改善急性心力衰竭(AHF)相关急性呼吸衰竭患者的临床体征尚不确定。
比较高流量氧疗与无创通气(NIV)对因 AHF 相关急性呼吸衰竭而入住急诊科(ED)的患者呼吸频率的影响。
设计、地点和参与者:这项多中心、前瞻性、随机试验在法国的三个 ED 中进行。纳入了因疑似 AHF 而出现急性呼吸衰竭的成年患者。主要排除标准为需要紧急插管、格拉斯哥昏迷量表(Glasgow Coma Scale)<13 分或血流动力学不稳定。
患者被随机分配接受高流量氧疗(最低 50 L/min)或双水平正压通气。
第一个小时内治疗后呼吸频率的变化为主要结局,采用线性混合模型进行分析。次要结局包括脉搏血氧饱和度、心率、血压、血气样本、舒适度、治疗失败和死亡率的变化。
在三个参与中心的 145 名合格患者中,60 名患者纳入分析[中位年龄 86(四分位距(IQR),90;92)岁]。高流量氧组和 NIV 组的中位呼吸频率分别为 30.5(IQR,28;33)和 29.5(IQR,27;35)次/分,高流量氧组的中位变化为-10(IQR,-12;-8)次/分,NIV 组为-7(IQR,-11;-5)次/分[估计差值-2.6 次/分(95%置信区间(CI),-0.5-5.7),P=0.052]。高流量氧组和 NIV 组的中位 SpO 2 分别为 95(IQR,92;97)和 96(IQR,93;97),高流量氧组在 60 分钟时的中位变化为 2(IQR,0;5),NIV 组为 2(IQR,-1;5)%[估计差值 0.8%(95%CI,-1.1-2.8),P=0.60]。两组在 1 小时时的 PaO 2 、PaCO 2 和 pH 均无差异,治疗失败、插管和死亡率也无差异。
在这项初步研究中,我们没有观察到因 AHF 导致急性呼吸衰竭且接受高流量氧疗或 NIV 治疗的患者呼吸率变化有统计学意义的差异。然而,点估计值及其较大的置信区间可能提示高流量氧疗有益。
NCT04971213(https://clinicaltrials.gov)。